Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

[Fix Long Study: A Factor Ix (Fix) Gene Transfer, Multi Center Evaluation Of The Long Term Safety And Efficacy Study Of Spk 9001 (Raav Spark100 Hfix Padua) In Individuals With Hemophilia B]

Trial Profile

[Fix Long Study: A Factor Ix (Fix) Gene Transfer, Multi Center Evaluation Of The Long Term Safety And Efficacy Study Of Spk 9001 (Raav Spark100 Hfix Padua) In Individuals With Hemophilia B]

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Feb 2019

At a glance

  • Drugs Fidanacogene-elaparvovec (Primary)
  • Indications Haemophilia B
  • Focus Adverse reactions
  • Acronyms FIX-LONG Study
  • Sponsors Spark Therapeutics
  • Most Recent Events

    • 11 Feb 2019 Planned End Date changed from 30 Mar 2024 to 29 Dec 2023.
    • 11 Feb 2019 Planned primary completion date changed from 30 Mar 2024 to 29 Dec 2023.
    • 09 Oct 2018 Planned number of patients changed from 15 to 20.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top